

Special Issue

Antibiotics vs. Phage Therapy, 2nd Edition

Message from the Guest Editor

The success of the Special Issue "[Antibiotics vs. Phage Therapy](#)" has encouraged us to open a second volume on the same topic. As a continuation of the Special Issue published in 2021, this second volume focuses on the comparison and interplay between antibiotics and phage therapy. Topics of interest include, but are not limited to, the following issues: (1) comparing the efficacy and safety of antibiotics and phage therapy, (2) the identification and characterization of newly discovered antimicrobial chemical agents and bacteriophages, and (3) assessment of the effectiveness of combined therapies using antibiotics together with bacteriophages to combat bacterial infections. Both original papers and review articles are welcome and will be considered for publication in this Special Issue of *Antibiotics*.

Guest Editor

Prof. Dr. Grzegorz Węgrzyn

Department of Molecular Biology, University of Gdańsk, Gdańsk, Poland

Deadline for manuscript submissions

closed (30 April 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/131305

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)